 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Gidazepam IC |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Eliminationhalf-life | ~87 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H15BrN4O2 |
| Molar mass | 387.237 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Gidazepam, also known ashydazepam orhidazepam,[2] is a drug which is an atypicalbenzodiazepine derivative, developed in theSoviet Union.[3][4] It is a selectivelyanxiolytic benzodiazepine.[5] It also has therapeutic value in the management of certain cardiovascular disorders.[6][7][8][9][10]
Gidazepam and several of its analogs, in contrast to other benzodiazepines, are comparatively more selective agonists ofTSPO (formerly the peripheral benzodiazepine receptor) than the benzodiazepine receptor.[5]
Gidazepam acts as aprodrug to its active metabolite 7-bromo-2,3-dihydro-5-phenyl-1H-1,4-benzodiazepin-2-one (desalkylgidazepam or bromo-nordazepam).[11][12] Its anxiolytic effects can take several hours to manifest presumably due to its slow metabolism (half-life 87 hours). The onset and intensity of anxiolytic effects correlate with blood levels of desalkylgidazepam.[13]
